It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
In modern drug discovery, speed and scale are everything. But achieving both, without compromising quality, requires more than great chemistry. It demands exceptional analytical and separation sciences, seamlessly integrated with your program from the very start.
At Sygnature Discovery, this is the standard we set.
Our separation sciences platform, featuring state-of-the-art SFC and HPLC technologies, is built to support your project through every stage of its journey. Whether you need a single isomer in high purity or 100 grams of a preclinical candidate, we don’t just deliver, we design the most efficient, cost-effective path to get you there.
Because for us, purification isn’t just a technical step. It’s a strategic advantage.
The Right Tool for the Right Molecule: HPLC vs. SFC
Our team approaches purification with the same mindset we bring to medicinal chemistry: one size never fits all. That’s why we leverage both high-performance liquid chromatography (HPLC) and supercritical fluid chromatography (SFC), switching between them or combining both based on your molecule’s physical properties and the phase of your project.
Here’s how we compare them:
Feature
HPLC
SFC
Solvent System
Organic + aqueous
CO₂-based + organic modifier
Chiral separations
Yes (longer runtimes)
Yes (faster, more efficient)
Speed
Slower
Rapid separation and shorter RT
Solvent consumption
High
Low (green and cost-efficient)
Best for…
Polar & aqueous molecules
Lipophilic, chiral, or apolar molecules
Scale-up readiness
Standard
Excellent via 30–50 mm prep columns
At Sygnature, this strategic flexibility allows us to consistently save time, reduce solvent use, and optimize resolution, from the first microgram to the last kilo.
Case-Backed Science: What This Means for Your Project
Let’s walk through what this looks like in practice, with real examples from our labs.
A compound’s solubility prevented HPLC analysis. We used a DCM/MeOH mix and…
Case Studies
A Strategic Asset in a Premium CRO Model
We’re not against GMP, in fact, when regulations require it, we’re fully supportive of making that step. But many of the activities during the transition from CRO-led preclinical to CDMO-led clinical development don’t need to be GMP from the outset. The regulations allow for flexibility, and using it wisely can save both time and budget without compromising quality.
Our approach helps customers:
Deliver at scale key intermediates that feed directly into GMP processes
Develop GMP-ready processes in advance so the CDMO can start with confidence
Consult strategically to help navigate the complex “grey zone” between preclinical and clinical, avoiding over-engineering where it’s not required
By staying alongside our clients during this transition, we help ensure the journey is cost-efficient, low-risk, and primed for success.
Conclusion: Let’s Build the Path to Kilo, Together
As your project grows, so does the complexity of what needs to be purified, analyzed, and delivered. Sygnature Discovery is uniquely positioned to take you from first injection to kilo-scale preparation, with science, speed, and strategy built in.
If you’re looking for a partner who understands that separation sciences are a gateway, not a gatekeeper, we’re ready to help you move forward, faster.
